Acc interventional cardiology board review 2023 năm 2024

The Iowa Chapter of the ACC along with ACC Early Career Chapter held

the Interventional Cardiology Board Review Zoom Lecture Series on Saturdays, August 1-22, 2020.

%20(1).png)

Course Director

Mahi Ashwath, MD, MBA, FACC, FASE, FSCMR

President, Iowa ACC Director, Cardiac MRI Clinical Associate Professor of Medicine and Radiology, Department of Internal Medicine University of Iowa e: [email protected]

@MahiAshwath

Planning Committee

Poonam Velagapudi, MD, MS, FACC Interventional Cardiologist University of Nebraska Medical Center Chair, Early Career Section of the American College of Cardiology e: [email protected] @Pooh_Velagapudi

Shubha Deep Roy MD

Cardiovascular Disease Fellow Chief Cardiology Fellow Co-chair Iowa ACC FIT Council Division of Cardiovascular Medicine University of Iowa e: [email protected]

Want to be a sponsor?

Download our request letter and sponsor form

To pay your sponsorship via credit card, Email us

Doug Drachman, MD, ACC.23 program chair and director of education and the interventional cardiology fellowship program, Massachusetts General Hospital, explains some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

According to Drachman, the top three late-breakers were the first ones presented at the ACC opening session.

The CLEAR Outcomes study showed benpedoic acid can be used in statin-intolerant patients to lower LDL cholesterol and improve outcomes.

"I think it is incredibly exciting to be able to use other medications for individuals who might be intolerant to taking statins," he explained.

The TRILUMINATE study showed the use of a transcatheter clip device to treat severe tricuspid valve regurgitation and improve quality of life. The current standard of care for tricuspid regurgitation is medical therapy, because surgical valve replacements generally have poor outcomes. Drachman said this new therapy will open the door to treating this unmet need patient population.

The STOP-CA study looked at the use of statin therapy as a way to reduce anthracycline cardio-toxicity during cancer chemotherapy. He said this trial will likely have a big impact on preventive care of cardio-oncology patients.

"Taking a statin for a year is a pretty innocuous therapy with very few downsides and this therapy can offer hope for patients that are already dealing with a new cancer diagnosis and will receive important therapies for their cancer that can also have cardio toxicity, and it is great that we now have an option that may help," Drachman explained.

On the interventional cardiology side of the late-breakers, the BIOVASC study of complete revascularization strategies in patients presenting with acute coronary syndromes and multivessel coronary disease will help inform how to best treat these patients.

"This is something we deal with all the time in the catheterization lab. We did find that immediate, full revascularization was non-inferior to the stage 3 revascularization approach and actually reduced the development of spontaneous myocardial infarction, or the need for unplanned additional revascularization," Drachman said. "That was something with a very important take-home message for us."

The five-year results of the COAPT study was also insightful, Drachman explained. This looked at the long-term outcomes of edge-to-edge repair (TEER) procedures using transcatheter clip devices to reduce mitral regurgitation in patients with severe heart failure. When data from this trial was first presented a few years ago at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting, it became an instant landmark study and changed how heart failure patients with MR are treated to relive their symptoms and improve their quality of life. Drachman said that positive data trend continued to five years out, helping reduce hospitalizations and death.

Another major heart health study looked at the association of a low-carbohydrate high-fat ketogenic diets, which found a keto diet raises LDL and results in a two-fold increase in adverse cardiovascular events.

Another study that looked at a new wrist-worn troponin sensor for patients presenting to emergency departments with chest pain may hold promise to reducing or eliminating regular interval blood draws to check cardiac enzyme levels, Drachman said.

What are the best cardiology trials for 2023?

Including trials in coronary imaging, transcatheter tricuspid valve interventions, transcatheter aortic valve implantation (TAVI) and further insights from the REVIVED-BCIS2 study are among the top research that came out of 2023 in interventional cardiology field.

What are the new advances in interventional cardiology?

Transcatheter aortic valve implantation (TAVI) has become an important treatment option for aortic stenosis, even among younger patients, with similar rates of efficacy as compared with surgical valve replacement.

What are the two most common cardiac interventional procedures?

The most common interventional cardiology procedure (catheterization) involves the insertion of a sheath into the groin or wrist artery and passing a catheter to the heart to open a blocked artery with balloon (angioplasty) or a stent (metal sleeve that is inserted to prop open the artery from within).

What is the difference between a cardiologist and an interventional cardiologist?

The major difference between interventional cardiology and general cardiology lies in the fact that interventional cardiologists are trained to perform specific catheter-based treatments for heart disease. General cardiologists on the other hand are not trained in those procedures.